Management of Breakthrough DVT on Apixaban

Initial Assessment and Investigation

• The American Society of Hematology recommends verifying medication adherence to confirm the patient has been taking apixaban as prescribed, including correct dosing frequency and timing 1
• Assess for underlying prothrombotic conditions, such as active malignancy, antiphospholipid syndrome, occult cancer, or other hypercoagulable states that may overwhelm standard anticoagulation 1

Recommended Anticoagulation Change

• The American Society of Hematology 2020 guidelines suggest switching to low molecular weight heparin (LMWH) as the preferred alternative anticoagulant for breakthrough thrombosis on apixaban, based on very low certainty evidence 1
• LMWH provides consistent anticoagulation with weight-based dosing and does not rely on the same pathways as apixaban 1

Alternative DOAC Considerations

• No evidence demonstrates superiority of one DOAC over another for VTE treatment, but switching to rivaroxaban or edoxaban may be considered if LMWH is not feasible 2, 3, 4
• Switch to dabigatran, a direct thrombin inhibitor with entirely different mechanism, may also be considered 2, 3

Specific Clinical Scenarios

• For cancer-associated thrombosis, LMWH remains preferred, particularly with breakthrough events 2, 3
• For antiphospholipid syndrome, DOACs should be avoided entirely, and switch to therapeutic LMWH or warfarin (target INR 2.0-3.0) 2, 3

Duration of Anticoagulation After Switch

• Minimum 3 months of therapeutic anticoagulation from the time of the breakthrough event 2, 3, 5
• Consider indefinite anticoagulation if no reversible cause is identified, as breakthrough thrombosis on therapeutic anticoagulation represents very high recurrence risk 5, 4